EKF Diagnostics (EKF) Competitors

MaxCyte (LON:MXCT) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.

Does the MarketBeat Community prefer MXCT or EKF?

EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.

Company	Underperform	Outperform
MaxCyte	Outperform Votes 153 68.92%	Underperform Votes 69 31.08%
EKF Diagnostics	Outperform Votes 327 76.76%	Underperform Votes 99 23.24%

Which has stronger earnings and valuation, MXCT or EKF?

EKF Diagnostics has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	£57.52M	4.72	-£45.08M	-£27.29	-7.54
EKF Diagnostics	£49.91M	2.03	£4.68M	£1.07	21.24

Do institutionals and insiders believe in MXCT or EKF?

70.5% of MaxCyte shares are owned by institutional investors. Comparatively, 70.3% of EKF Diagnostics shares are owned by institutional investors. 1.5% of MaxCyte shares are owned by insiders. Comparatively, 5.2% of EKF Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media refer more to MXCT or EKF?

In the previous week, MaxCyte had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 2 mentions for MaxCyte and 1 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 1.37 beat MaxCyte's score of -0.67 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
EKF Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is MXCT or EKF more profitable?

EKF Diagnostics has a net margin of 9.37% compared to MaxCyte's net margin of -78.37%. EKF Diagnostics' return on equity of 7.03% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-78.37%	-16.01%	-11.07%
EKF Diagnostics	9.37%	7.03%	5.27%

Which has more volatility & risk, MXCT or EKF?

MaxCyte has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Summary

EKF Diagnostics beats MaxCyte on 10 of the 15 factors compared between the two stocks.